سعر ثروموكسيبان Thromoxiban‏ 15مجم 10 اقراص 2026

Rivaroxaban 15 mg oral tablets (direct factor Xa inhibitor anticoagulant), Egyptian generic, 10 tablets.

• Most common adverse reaction in adults (>5%): bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Active pathological bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant if stopped for reasons other than bleeding or completion of therapy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: epidural or spinal haematomas with neuraxial anaesthesia or spinal puncture, which may cause long-term or permanent paralysis; monitor neurological status.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Bleeding risk; the anticoagulant effect cannot be reliably monitored with standard laboratory tests.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid.DailyMed (U.S. National Library of Medicine)
• Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease exposure and may increase thromboembolic risk; avoid.DailyMed (U.S. National Library of Medicine)
• Other anticoagulantsAvoid concomitant use.DailyMed (U.S. National Library of Medicine)

• Limited data are insufficient to inform drug-associated risk; use with caution because of pregnancy-related haemorrhage and/or emergent delivery risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Rivaroxaban has been detected in human milk; weigh breastfeeding benefits against maternal need and possible infant effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Rivaroxaban: Highly selective direct factor Xa inhibitor with oral bioavailability; inhibition of factor Xa interrupts the intrinsic and extrinsic coagulation pathways, inhibiting thrombin formation and thrombus development; does not inhibit thrombin and has no demonstrated effect on platelets (EU SmPC).